When it comes to weight loss, Arena Pharmaceuticals is throwing in the towel.
The small San Diego biotech company had once expected its anti-obesity drug, Belviq, to be a blockbuster — after all, more than one-third of Americans are obese. But the market wasn’t interested, and sales never lived up to expectations — leading the company to slash its employee count by 120, nearly three-quarters of its workforce.
About the Author Reprints
Useful Info. Check out this step by step video on 3 week diet program; https://goo.gl/vBmgQg
I’m confused by the discussion of a cardiovascular outcomes trial (CVOT) for Belviq in this article. I’ve read that the company already has a CVOT called CAMELLIA-TIMI 61 in progress. My understanding was that this study had completed enrollment in December 2015 and is expected to finish in the summer of 2018. So, hasn’t the $80 million investment for the CVOT already been made? Or is additional money needed to support the trial?
https://www.clinicaltrials.gov/show/NCT02019264
http://www.prnewswire.com/news-releases/eisai-and-arena-pharmaceuticals-announce-completion-of-enrollment-in-belviq-lorcaserin-hci-camellia-timi-61-study-300185958.html